Alcon Inc.: management transactions · Switzerland · SIX SER

About Alcon Inc.

Alcon Inc. is a global eye-care company listed on the SIX Swiss Exchange (SMI/SPI) and domiciled in Switzerland, with its global headquarters in Geneva. The company is one of the world’s leading ophthalmology names, with a strong position in both surgical eye care and vision care. Its roots go back to 1945, when it was founded in Fort Worth, Texas, by two pharmacists. After decades as part of Novartis, Alcon was separated into an independent public company in 2019. Alcon’s business model is built around two core segments: Surgical and Vision Care. The Surgical division includes equipment, consumables and systems used in cataract, refractive and vitreoretinal procedures, as well as phacoemulsification platforms, lasers, implants and related surgical instruments. The Vision Care segment covers contact lenses, lens care products, artificial tears and other eye-health and comfort products. This dual structure gives Alcon exposure to both high-innovation medical devices and recurring consumer-oriented eye-care demand. From a competitive standpoint, Alcon holds a solid position in a highly specialized global market that features high barriers to entry, meaningful regulatory hurdles and a constant need for clinical innovation. The company benefits from a large installed base of surgical equipment, a recognized brand and a broad portfolio spanning the eye-care continuum. It is commonly regarded as the global leader in eye-care devices, with commercial reach across North America, Europe, Asia-Pacific and emerging markets, supported by R&D, manufacturing and distribution capabilities in multiple geographies. Key products and solutions include cataract surgery platforms, surgical visualization and aspiration systems, Air Optix and DAILIES contact lenses, as well as products addressing dry eye and everyday visual comfort. Alcon regularly highlights new product launches and technological advances, which support its defensive profile and its ability to refresh the portfolio over time. Recent developments have centered on innovation and strategic M&A. In 2025, Alcon announced new product launches and disclosed acquisition activity, including LENSAR and an amended agreement to acquire STAAR Surgical, strengthening its position in refractive surgery and laser-enabled vision correction solutions. For investors, Alcon offers a quality healthcare exposure, global diversification and a long-term growth profile supported by demographic aging and structural demand for eye care.